Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

TRAIL-Expressing Monocyte/Macrophages Are Critical for Reducing Inflammation and Atherosclerosis.

Title: TRAIL-Expressing Monocyte/Macrophages Are Critical for Reducing Inflammation and Atherosclerosis.
Authors: Cartland, Siân P; Genner, Scott W; Martínez, Gonzalo J; Robertson, Stacy; Kockx, Maaike; Lin, Ruby Cy; O'Sullivan, John F; Koay, Yen Chin; Manuneedhi Cholan, Pradeep; Kebede, Melkam A; Murphy, Andrew J; Masters, Seth; Bennett, Martin R; Jessup, Wendy; Kritharides, Leonard; Geczy, Carolyn; Patel, Sanjay; Kavurma, Mary M
Publisher Information: Elsevier; //doi.org/10.1016/j.isci.2018.12.037
Publication Year: 2019
Collection: Apollo - University of Cambridge Repository
Subject Terms: Diabetology; Immune Response; Immunology; Molecular Mechanism of Behavior; Pathophysiology
Description: Circulating tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) levels are reduced in patients with cardiovascular disease, and TRAIL gene deletion in mice exacerbates atherosclerosis and inflammation. How TRAIL protects against atherosclerosis and why levels are reduced in disease is unknown. Here, multiple strategies were used to identify the protective source of TRAIL and its mechanism(s) of action. Samples from patients with coronary artery disease and bone-marrow transplantation experiments in mice lacking TRAIL revealed monocytes/macrophages as the main protective source. Accordingly, deletion of TRAIL caused a more inflammatory macrophage with reduced migration, displaying impaired reverse cholesterol efflux and efferocytosis. Furthermore, interleukin (IL)-18, commonly increased in plasma of patients with cardiovascular disease, negatively regulated TRAIL transcription and gene expression, revealing an IL-18-TRAIL axis. These findings demonstrate that TRAIL is protective of atherosclerosis by modulating monocyte/macrophage phenotype and function. Manipulating TRAIL levels in these cells highlights a different therapeutic avenue in the treatment of cardiovascular disease.
Document Type: article in journal/newspaper
File Description: Print-Electronic; application/pdf
Language: English
Relation: https://www.repository.cam.ac.uk/handle/1810/290678
DOI: 10.17863/CAM.37885
Availability: https://www.repository.cam.ac.uk/handle/1810/290678; https://doi.org/10.17863/CAM.37885
Rights: Attribution-NonCommercial-NoDerivatives 4.0 International ; https://creativecommons.org/licenses/by-nc-nd/4.0/
Accession Number: edsbas.58626AFA
Database: BASE